- Home
- KDK vs URGN Comparison
KDK vs URGN Comparison
Compare KDK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KDK
- URGN
- Stock Information
- Founded
- KDK 2018
- URGN 2004
- Country
- KDK United States
- URGN United States
- Employees
- KDK N/A
- URGN N/A
- Industry
- KDK EDP Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- KDK Technology
- URGN Health Care
- Exchange
- KDK Nasdaq
- URGN Nasdaq
- Market Cap
- KDK 1.3B
- URGN 1.1B
- IPO Year
- KDK N/A
- URGN 2017
- Fundamental
- Price
- KDK $6.28
- URGN $25.43
- Analyst Decision
- KDK Strong Buy
- URGN Strong Buy
- Analyst Count
- KDK 4
- URGN 8
- Target Price
- KDK $15.63
- URGN $28.50
- AVG Volume (30 Days)
- KDK 535.6K
- URGN 1.3M
- Earning Date
- KDK 11-12-2025
- URGN 11-06-2025
- Dividend Yield
- KDK N/A
- URGN N/A
- EPS Growth
- KDK N/A
- URGN N/A
- EPS
- KDK N/A
- URGN N/A
- Revenue
- KDK $16,450,000.00
- URGN $96,516,000.00
- Revenue This Year
- KDK N/A
- URGN $35.07
- Revenue Next Year
- KDK N/A
- URGN $117.83
- P/E Ratio
- KDK N/A
- URGN N/A
- Revenue Growth
- KDK N/A
- URGN 8.00
- 52 Week Low
- KDK $5.77
- URGN $3.42
- 52 Week High
- KDK $11.62
- URGN $25.60
- Technical
- Relative Strength Index (RSI)
- KDK N/A
- URGN 70.50
- Support Level
- KDK N/A
- URGN $22.70
- Resistance Level
- KDK N/A
- URGN $24.89
- Average True Range (ATR)
- KDK 0.00
- URGN 1.87
- MACD
- KDK 0.00
- URGN 0.24
- Stochastic Oscillator
- KDK 0.00
- URGN 99.19
About KDK Kodiak AI Inc. Common Stock
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.